A$4.10 AYA.AX Artrya Limited ASX after hours: AI traction but valuation questions
AYA.AX stock trades at A$4.10 after hours on the ASX on 19 Jan 2026, up 2.24% on the session as investors weigh Artrya Limited’s AI adoption against stretched valuation. The company offers Salix, an AI tool for coronary artery disease detection, and recent buying interest pushed volume to 813,779 shares today. Key metrics show momentum—50-day average A$3.89 and 200-day average A$2.10—but earnings remain negative with EPS -0.18 and PE -24.22. We review trading activity, financial ratios, technicals, and Meyka AI model forecasts to frame an investment view for healthcare AI investors.
AYA.AX stock snapshot: price, volume and market cap
Artrya Limited (AYA.AX) closed after hours at A$4.10, up A$0.09 or 2.24%, with intraday high A$4.47 and low A$4.08. Market capitalisation stands at A$494,075,200 and circulating shares are 113,320,000, while average daily volume is 870,263 so today’s 813,779 shares matched typical turnover.
AYA.AX stock financials: losses, cash and ratios
Artrya reports EPS -0.18 and a negative PE of -24.22, reflecting ongoing R&D and operating losses. The balance sheet shows A$0.11 cash per share, a strong current ratio 8.27, low debt to equity 0.03, and price to book 21.10, highlighting high market value versus book.
AYA.AX stock technicals: momentum and overbought signals
Momentum indicators show strength: RSI 70.89 (overbought) and ADX 40.86 indicating a strong trend, while MACD histogram is 0.09, supporting recent upside. Volatility is present: ATR 0.32, Bollinger Bands middle A$4.20, upper A$5.17, lower A$3.23, suggesting wider intraday swings ahead.
Meyka grade & valuation: score and analyst context
Meyka AI rates AYA.AX with a score of 59.14 out of 100 (C+, HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts and analyst consensus, and is informational only, not financial advice.
AYA.AX stock outlook & Meyka AI forecast
Meyka AI’s forecast model projects a 12‑month target of A$7.30, implying +78.04% upside from the current A$4.10; forecasts are model-based projections and not guarantees. Near term, market focus will be on the earnings announcement scheduled for 24 Feb 2026 and adoption updates for Salix in clinical workflows.
Risks and opportunities for AI investors in AYA.AX stock
Opportunity stems from AI demand in medical imaging and Artrya’s Salix platform adoption, which could drive revenue if clinical rollouts scale. Risks include sustained negative margins, extreme valuation metrics like price to sales 17,645.54, and execution gaps in commercialisation that could pressure the share price.
Final Thoughts
Key takeaways for AYA.AX stock: Artrya trades at A$4.10 after hours on the ASX with solid intraday momentum but a stretched valuation relative to book and near-term losses. Technicals show a strong trend and overbought conditions, while fundamentals show cash buffers and low debt but persistent negative margins and heavy R&D spend. Meyka AI’s forecast model projects A$7.30 in 12 months, implying +78.04% upside versus A$4.10 today, yet that projection carries model risk and relies on execution of clinical rollouts and revenue growth. Investors focused on AI stocks should balance the growth case for diagnostic AI against high price-to-book and negative profitability. Monitor the upcoming earnings report on 24 Feb 2026, adoption milestones for Salix, and sector reimbursement trends. For more detail see our data page at Meyka AYA page and latest market coverage from Markets Business Insider. Meyka AI provides this AI-powered market analysis; use it with your own research before trading.
FAQs
What is the current price of AYA.AX stock?
AYA.AX stock trades at A$4.10 after hours on 19 Jan 2026, with a day range of A$4.08–A$4.47 and volume 813,779 shares today. Check live quotes for intraday moves.
When is Artrya’s next earnings announcement?
Artrya Limited has an earnings announcement scheduled for 24 Feb 2026. Investors should watch that report for revenue trends, guidance and updates on Salix adoption.
What is Meyka AI’s rating for AYA.AX?
Meyka AI rates AYA.AX 59.14/100 (C+, HOLD) based on benchmark, sector, growth, metrics and analyst inputs; this is informational and not investment advice.
What upside does the Meyka forecast imply for AYA.AX stock?
Meyka AI’s forecast model projects A$7.30 in 12 months, implying +78.04% upside from A$4.10 today; forecasts are model-based projections and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
